Objective: To review the evidence for antiretroviral 'treatment as prevention' for HIV transmission among MSM.
Introduction
One randomized controlled trial [1] and numerous observational studies [2] [3] [4] [5] [6] provide strong evidence that antiretroviral therapy (ART) can reduce or prevent the sexual transmission of HIV-1 within serodiscordant heterosexual couples. A key question remains: does ART reduce HIV transmission among men who have sex with men (MSM), in which case the primary mode of transmission is via condomless anal intercourse? New WHO guidelines for earlier initiation of ART among serodiscordant couples were released in April 2012 [7] , and some countries, such as China, have already embraced treatment as prevention (TasP) for heterosexual couples. In the process of re-evaluating current ART guidelines, we anticipate that for some countries, the issue of whether to recommend TasP for MSM will be under debate. The evidence supporting TasP for MSM is promising, but major gaps in our knowledge remain. To identify priority areas for research, in this study, we synthesize evidence from studies of MSM of the biological plausibility that virally suppressive ART reduces HIV infectiousness via anal intercourse and epidemiologic evidence of whether ART has played a role in attenuating HIV incidence. Some biological and epidemiological evidence suggests that ART for preventing transmission via anal intercourse may have more limited efficacy than via vaginal intercourse. Without ART, the probability of HIV transmission is estimated as 1 infection for every 20-300 acts of condomless anal intercourse, as compared to one in 200 to one in 2000 for penile-vaginal exposure [8] [9] [10] [11] [12] [13] . Additionally, a higher median number of HIV variants are transmitted in MSM couples as compared to heterosexual couples [14, 15] , potentially posing greater challenges for drug resistance [16] .
The pharmacology of antiretroviral agents also differs between the urogenital tract (vaginal intercourse) and the gastrointestinal tract (anal intercourse). Antiretroviral drugs can reduce -but not eliminate -the amount of HIV recovered from the genital tract [17] [18] [19] and gastrointestinal tract [20] [21] [22] . Higher levels of HIV DNA and RNA have been found in the gastrointestinal tract (duodenum, ileum, ascending colon, and rectum) as compared to the blood [23, 24] and semen [22] , irrespective of ART use, although these levels may be positively correlated [20, 25, 26] . Some antiretrovirals such as tenofovir, tenofovir diphosphate, and maraviroc have been shown to penetrate rectal tissue with greater efficiency than blood or seminal plasma [27, 28] , but the durability of this penetration and required levels for prevention are not yet established. Furthermore, paired blood and rectal biopsy samples tested for resistance to antiretrovirals have shown different mutation profiles in the virus recovered from each site [29] . This would suggest that replication can persist in the rectum even if a patient appears otherwise virally suppressed. Although the results of the HIV Prevention Trials Network 052 randomized trial among serodiscordant couples (HPTN 052) demonstrated the capacity of antiretroviral drugs to markedly reduce the risk of penile-vaginal transmission [1] despite similar biological and pharmacokinetic uncertainties, we cannot be certain that this will be the case for anal intercourse given the much higher transmission probability in the absence of ART.
In addition, we do not know the extent to which sexual risk behaviors might offset the potential prevention benefits of ART. Increases in bacterial sexually transmitted infections (STIs) are compelling evidence of ongoing high-risk behaviors among MSM [30] [31] [32] [33] [34] , and these co-infections amplify HIV transmission [35] [36] [37] [38] [39] [40] . Globally, there is evidence of increases in STIs among MSM including rectal gonorrhea [30, 32, 33, 41] , urethral gonorrhea [42] , and syphilis [32, 33, [43] [44] [45] . Other behaviors such as serosorting (limiting sexual partners to those thought to be of the same HIV serostatus) [46] and rectal douching [47] also alter the risk of HIV transmission among MSM.
We do not know the extent to which sexual risk behaviors among MSM are changing due to the increasing availability of ART. Positive beliefs about the protective ability of ART (treatment optimism) [48] [49] [50] [51] and being on ART itself [50, 52, 53] , irrespective of actual viral suppression, have been associated with increased condomless anal intercourse. A metaanalytic review of studies published between 1996 and 2003 found a nonsignificant association between taking ART and increased condomless anal intercourse among MSM [odds ratio (OR) 1.38, 95% confidence interval (CI) 0.62-3.07]; however, the belief that being on ART protects against transmission was associated with an almost two-fold increase in condomless anal intercourse (OR 1.84, 95% CI 1.53-2.20) [54] . The number of studies on these impacts of ART on behavior has more than doubled since this review, and an updated meta-analysis has been commissioned by the WHO with results anticipated in 2012. Changes in transmission risk behaviors are also being assessed as a secondary outcome in the randomized controlled START trial (Strategic Timing of Antiretroviral Treatment), a study among treatment-naive, HIVpositive persons recruited from over 200 sites worldwide comparing initiation of ART at CD4 cell count greater than 500 cells/ml to initiation at less than 350 cells/ml [55] .
Observational studies of whether ART reduces HIV transmission among MSM produce mixed findings. Surveillance data and longitudinal cohort studies suggest that HIV incidence among MSM has fluctuated, in some cases increasing, in spite of widespread ART availability [41] [42] [43] [56] [57] [58] [59] [60] [61] [62] . To estimate how ART has affected HIV transmission among MSM, some studies have calculated a per-partner or per-act transmission risk and compared these rates pre and post highly active antiretroviral therapy (HAART) [13, 63] . For example, the Health in Men Australian cohort (2001-2007) used behavioral risk data and annual HIV-incident infections to estimate per-contact HIV transmission risk. In Sydney -with overall stable incidence of HIV and increasing uptake of ART -the authors conclude that the overall per-contact risk of transmission has not changed in spite of increased ART coverage and more effective regimens [13] .
Other studies have combined HIV surveillance and/or cohort data from communities with high ART coverage to compare trends in ART use and transmission (Table 1 ) [42, 56, [64] [65] [66] . For instance, one older study in San Francisco (1995-1999) using community surveillance and clinic data concluded that any decrease in HIV infectivity gained by widespread use of ART may have been offset by increases in condomless anal intercourse and/or STIs [56] . A more recent San Francisco study using HIV surveillance data (2004-2008) described a significant correlation between decreased annual mean community viral load (CVL, an aggregate measure of the total known viral load among a particular population) and decreases in newly diagnosed cases of HIV; however, the association with HIV incidence measured with the BED capture enzyme immunoassay was not statistically significant [64] . A similar study using surveillance data (2004-2008) from Washington, DC, found a decrease in mean CVL and an increase in the proportion of known HIV-positive persons virally suppressed, but a statistically significant increase in newly diagnosed cases of HIV [66] . In these data, MSM had the highest proportion of individuals with undetectable viral load compared with other risk groups; however, black MSM were less likely to have undetectable viral load compared to white MSM [66] . A study conducted in Vancouver reported similar associations between decreases in CVL and new HIV diagnoses [42] however, the role of injection drug use in driving these trends is unclear [67, 68] , and government surveillance reports show fluctuations in new HIV diagnoses among MSM in British Columbia with no overall change compared to 2003 [62] . Among Vancouver MSM specifically, HIV prevalence is steady and slightly rising, likely reflecting increases in survival as well as new diagnoses [69] . In contrast, a study from Denmark using national HIV surveillance and clinic data showed that rising proportions of HIV-infected MSM on suppressive treatment were correlated with stable rates of new HIV diagnoses in spite of increasing proportions of MSM reporting condomless anal intercourse [65] .
Due to their reliance on aggregate data and on new diagnosis reports rather than on new incident infections, these ecological studies are unable to draw causal inferences about the individual-level processes driving transmission. Their mixed results suggest that characteristics of specific geographic epidemics as well as behavioral patterns likely contribute to the populationlevel impact of ART on HIV transmission among MSM.
The majority of data available for the impact of ART among MSM are from developed countries in North America, Western Europe, and Australia. As a result, what we know about ART's effect on HIV transmission comes from a small subset of MSM, limiting the generalizability of these results within other social, cultural, and epidemic settings. While recognizing the barriers of stigma, discrimination, and legal repercussions, it is clear that more research is needed in this regard among MSM populations in South America, Africa, Central Europe, and Asia. In order to inform optimal ART recommendations, we also need to better understand the social and cultural environments in which new sexual behavioral trends are evolving.
Going forward, there are great opportunities to further our understanding of the individual and population-level transmission dynamics of HIV and ART among MSM. For example, applying the tools of phylogenetic analysis, researchers may be able to identify the most likely source of an individual's HIV infection, describe the size and distribution of clusters of new cases in the population and assess the relative contributions to new transmissions by persons at various stages of infection. For example, a study utilizing phylogenetic methods among MSM in the UK identified the following characteristics as likely to contribute disproportionately to onward HIV transmission: recent infection, not receiving ART, and concomitant STI [70] . Whereas an individual-level randomized clinical trial to directly evaluate the efficacy of ART for prevention in MSM may not be feasible or ethical [71] , well designed observational studies of seroconcordant and discordant couples -as reported with heterosexual individuals [3, 4] -allow researchers to measure the risk of acquiring and transmitting HIV. Two such studies involving MSM couples in Europe and Australia are currently enrolling or planned [72, 73] .
The benefits of TasP for MSM are highly plausible, but not certain. The results of HPTN 052 have generated great urgency for maximizing the prevention benefit of ART. However, the impact of ART on HIV transmission via anal intercourse requires further evaluation due to the inconclusive observational data currently available for MSM and the challenging biological and behavioral risk factors that may be present. If TasP becomes part of prevention policy for MSM, it will be critical to earlier treatment in combination with HIV diagnosis, continued structural and behavioral interventions, and expanded STI treatment and prevention. The views expressed herein do not reflect the official stance of any funding agencies. We have no conflicts of interests to declare.
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